Pediatrics

Episodes 1-5 of 5

• 

  RestartResume

  The Crohn’s & Colitis Foundation's Camp Oasis: A Clinician's Perspective

  RestartResume

  The Crohn’s & Colitis Foundation's Camp Oasis: A Clinician's Perspective

  Crohn’s & Colitis Foundation Perspectives

  The Crohn’s & Colitis Foundation's Camp Oasis: A Clinician's Perspective

  • 

    

    Philip Stein, MD

    Peer

  • 

    

    Neilanjan Nandi, MD

    Peer

  • 

    

    Susan Peck, MSN, CRNP

    Peer

• 

  RestartResume

  Heart of the Matter: Emerging Treatment Options for Congenital Heart Disease

  RestartResume

  Heart of the Matter: Emerging Treatment Options for Congenital Heart Disease

  Clinician's Roundtable

  Heart of the Matter: Emerging Treatment Options for Congenital Heart Disease

  • 

    

    John Russell, MD

    Peer

  • 

    

    Thomas Doyle, MD

    Peer

• 

  RestartResume

  Anti-TNFα Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure

  RestartResume

  Anti-TNFα Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure

  AudioAbstracts

  Anti-TNFα Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure

• 

  RestartResume

  Growing Up With IBD: When to Transition to an Adult GI Specialist

  RestartResume

  Growing Up With IBD: When to Transition to an Adult GI Specialist

  Crohn’s & Colitis Foundation Perspectives

  Growing Up With IBD: When to Transition to an Adult GI Specialist

  • 

    

    Adam Ehrlich, MD, MPH

    Peer

  • 

    

    Philip Stein, MD

    Peer

• 

  RestartResume

  Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

  RestartResume

  Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

  AudioAbstracts

  Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy